{"title":"Myrtenol mitigates seizure activity and oxidative imbalance in a mouse model of PTZ-induced seizure.","authors":"Fatemeh Rasouli, Seyed Hesam Hojjat, Farzaneh Shakeri","doi":"10.1080/00207454.2026.2749811","DOIUrl":null,"url":null,"abstract":"<p><p>Pentylenetetrazole (PTZ)-induced seizures are strongly associated with oxidative imbalance, and the monoterpenoid alcohol myrtenol has been proposed to exert antioxidant and neuroprotective effects. This study investigated whether myrtenol attenuates PTZ-evoked seizure activity and oxidative disturbances in the mouse hippocampus and cerebral cortex. Sixty male mice were assigned to six groups: control, PTZ-only, three myrtenol pretreatment doses (25, 50, 100 mg/kg), and diazepam. Seizure susceptibility was evaluated by measuring latencies to minimal clonic and generalized tonic-clonic seizures following PTZ administration. Oxidative stress markers, including malondialdehyde (MDA), nitric oxide (NO), superoxide dismutase (SOD), catalase (CAT), and total thiol content, were quantified in brain homogenates. PTZ reliably induced seizures and oxidative alterations. Myrtenol pretreatment increased seizure latencies in a dose-dependent manner, although diazepam produced the greatest protection. Myrtenol, particularly at 100 mg/kg, reduced PTZ-induced elevations in MDA and NO, restored SOD and CAT activities, and improved thiol levels, with effects approaching those of diazepam. Lower myrtenol doses produced partial or nonsignificant biochemical improvements. These findings indicate that myrtenol mitigates PTZ-induced seizure expression and oxidative stress, with the highest dose demonstrating the most consistent neuroprotective profile.</p>","PeriodicalId":14161,"journal":{"name":"International Journal of Neuroscience","volume":" ","pages":"1-17"},"PeriodicalIF":1.7000,"publicationDate":"2026-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Neuroscience","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/00207454.2026.2749811","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"NEUROSCIENCES","Score":null,"Total":0}
引用次数: 0
Abstract
Pentylenetetrazole (PTZ)-induced seizures are strongly associated with oxidative imbalance, and the monoterpenoid alcohol myrtenol has been proposed to exert antioxidant and neuroprotective effects. This study investigated whether myrtenol attenuates PTZ-evoked seizure activity and oxidative disturbances in the mouse hippocampus and cerebral cortex. Sixty male mice were assigned to six groups: control, PTZ-only, three myrtenol pretreatment doses (25, 50, 100 mg/kg), and diazepam. Seizure susceptibility was evaluated by measuring latencies to minimal clonic and generalized tonic-clonic seizures following PTZ administration. Oxidative stress markers, including malondialdehyde (MDA), nitric oxide (NO), superoxide dismutase (SOD), catalase (CAT), and total thiol content, were quantified in brain homogenates. PTZ reliably induced seizures and oxidative alterations. Myrtenol pretreatment increased seizure latencies in a dose-dependent manner, although diazepam produced the greatest protection. Myrtenol, particularly at 100 mg/kg, reduced PTZ-induced elevations in MDA and NO, restored SOD and CAT activities, and improved thiol levels, with effects approaching those of diazepam. Lower myrtenol doses produced partial or nonsignificant biochemical improvements. These findings indicate that myrtenol mitigates PTZ-induced seizure expression and oxidative stress, with the highest dose demonstrating the most consistent neuroprotective profile.
期刊介绍:
The International Journal of Neuroscience publishes original research articles, reviews, brief scientific reports, case studies, letters to the editor and book reviews concerned with problems of the nervous system and related clinical studies, epidemiology, neuropathology, medical and surgical treatment options and outcomes, neuropsychology and other topics related to the research and care of persons with neurologic disorders. The focus of the journal is clinical and transitional research. Topics covered include but are not limited to: ALS, ataxia, autism, brain tumors, child neurology, demyelinating diseases, epilepsy, genetics, headache, lysosomal storage disease, mitochondrial dysfunction, movement disorders, multiple sclerosis, myopathy, neurodegenerative diseases, neuromuscular disorders, neuropharmacology, neuropsychiatry, neuropsychology, pain, sleep disorders, stroke, and other areas related to the neurosciences.